HEALTH

Acetaminophen products to undergo changes following advisory committee’s votes

BY Michael Johnsen

NEW YORK While the impetus for this multiple advisory committee meeting and the Food and Drug Administration’s working group that first examined this issue had been in the works long before the Obama administration took office — and consequently the new FDA took hold — there has been some concern that an overly zealous agency is placing any shred of safety concern ahead of consumer access — no matter how miniscule that safety risk may be.

 

In that regard, and so long as the FDA acts on the recommendations made by its advisory committees as is typical, the outcome of last week’s meeting isn’t as bad as it could have been. Combination APAP products are likely not to be recalled, which is good news beyond just McNeil Consumer and its Tylenol franchise. Also what-would-have-been-costly pack-size limitations, such as limiting the number of daily doses merchandised in each SKU to no more than three appears to also be off the table based on committee recommendations.

 

 

Those two actions would have been costly to manufacturers and retailers alike, especially as that would have resulted in a potential wholesale recall of products already in the supply chain. And if manufacturers are able to sell-through the current maximum dosing of 1,000 mg, then the overall cost to the industry will be relatively less.

 

 

 

The problem that remains, however, is public perception around the safety of acetaminophen, which by all accounts is safe when used as directed. And that’s going to be a problem in the coming weeks as the story of the committee meeting makes its way through the news cycle, and again when the FDA announces any changes it will make regarding the sale of OTC and prescription-only acetaminophen products in the coming months.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

LIVE FROM MARKETPLACE: Tears of joy

BY Drug Store News Team

WOBURN, Mass. Dubbed as the potential “next generation” of dry eye products, Advanced Vision Research is working toward a spring 2010 launch of its TheraTears Xtra.

The new dry eye solution contains trehalose, and all-natural ingredient with high water-retention capabilities. And while “trehalose” may not mean much to consumers, this will — TheraTears Xtra makes their dry eyes feel better faster and longer.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

LIVE FROM MARKETPLACE: Mederma launches stretch mark therapy

BY Drug Store News Team

GREENSBORO, N.C. Shipping in January 2010, Merz Pharmaceuticals is branching its Mederma scar brand out into a new area that ought to find quite a bit of traction among both new moms and female baby boomers — Mederma Stretch Marks Therapy. According to Merz, 85% of women have stretch marks.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES